Merck, Hit With First Fosamax Verdict, Challenges Plaintiff's Closing Arguments
This article was originally published in The Pink Sheet Daily
Firm hopes to negate $8 million verdict through post-trial motions.
You may also be interested in...
After two bellwether cases, Merck has yet to lose and the next case involves a company-chosen defendant.
Celgene will get exclusive use of Quanticel's single-cell genomic analysis to tweak its clinical pipeline, and it also has exclusive options to acquire the venture-backed start-up.
With an unrestricted label and once-daily dosing, rivaroxaban will do battle with Boehringer-Ingelheim's dabigatran, which is dosed twice a day but can claim superior efficacy to warfarin in the atrial fibrillation population.